Seeking men and women with HER2-positive breast cancer for a study comparing the usual multi-drug chemotherapy to a single chemotherapy drug and HER-2 therapy.
Participants in this study will receive 12 weeks of chemotherapy with a single drug and HER-2 therapy before surgery. Following successful surgery to remove the cancer, patients would continue to receive HER-2 therapy for a year and any other radiation and/or hormonal therapy advised by their doctor.
What we're hoping for
We are studying whether treatment with HER-2 therapy would allow for a reduction in the number of chemotherapy drugs needed to treat HER-2 positive breast cancer.
ClinicalTrials.gov Identifier: NCT04266249